A seven-person medical affairs team pulling forty papers a month at $42 each is spending $20,000 a year on PDFs that nobody can find again. The math gets uglier when two people on the team buy the same paper because there’s no shared library. But having a separate library means the team has to check the library every time to make sure they are not buying a duplicate copy, adding to their growing list of tasks.
The real corporate access problem is whether a team of users can get, use, store, and re-use the same paper without violating copyrights. Finding the paper turns out to be the easy part.
Most companies operate in a quiet patchwork: one researcher buys a paper with a personal card and expenses it, another grabs open access copies when PMC has them, a third emails a former PI for a PDF, and a regulatory analyst reads just the abstract because the article is too expensive to justify on their cost center. That arrangement may work for small organizations, but it does not scale as the organization grows.
Who this is for
Teams reading scientific literature as part of an R&D or regulatory function:
- R&D and discovery teams at biotechs (anywhere from a 12-person seed-stage startup to a 200-person clinical-stage company)
- Medical affairs, pharmacovigilance, and regulatory affairs teams supporting marketed products
- IP and patent monitoring teams running prior art searches and freedom-to-operate analyses
- Competitive intelligence and market access functions
- Medical communications agencies producing client deliverables under copyright scrutiny
- Corporate research groups outside life sciences (chemicals, materials, ag, energy) that still depend on paywalled journals
If you’re a solo independent researcher or a student, this isn’t the post for you. The risk calculus is different when the entity reading the paper is a legal person with a compliance function.
Why “free” stops being free in a company
Open access is great, but finding “free” copies of paywalled articles can be extremely time consuming and may be in violation of copyright laws. The article price is still the smallest line in what corporate access actually costs.
Inside a company, that cost also includes the analyst-hour spent re-finding a paper a colleague already bought, the unclear redistribution rights on a publisher-purchased PDF that ended up in a shared network drive, the duplicate purchases that don’t show up until the corporate card statement, and the missing audit trail when a regulator asks which references supported a benefit-risk assessment. None of that hits a per-article invoice, but all of it shows up on someone’s plate eventually.
The pattern is consistent across the small biotechs we talk to. Once a team crosses roughly twenty (20) article purchases a month, the ad-hoc model stops being cheaper than a structured one; the cost moves into headcount and risk.
The legal options, compared
| Option | Best for | What works well | Where it breaks down for companies |
|---|---|---|---|
| Open access and PubMed Central | First-pass searching; baseline coverage | Free, legal, immediate; growing share of biomed literature | Coverage gaps remain large in chemistry, engineering, older clinical literature |
| Direct publisher purchase | One-off urgent papers when relevance is already clear | $30-$50 per article, immediate | No deduplication, no shared archive, expenses scatter across cards |
| Interlibrary loan via a public library | Occasional edge cases for individuals | Often free | Slow turnaround, awkward for corporate use, limited rights for redistribution |
| Document delivery vendors (Reprints Desk, CCC’s RightFind, Copyright Clearance) | Hard-to-get papers; copyright-cleared use | Broad catalog, defensible licensing | Per-transaction cost; can run $35-$50 per article plus copyright fees |
| Institutional site licenses (Elsevier ScienceDirect, Wiley Online Library, Springer Nature) | Large pharma and big-tech R&D with predictable demand | Broad coverage if you negotiate the right titles | Six-figure annual minimums; often overbuilt for teams under fifty researchers |
| Centralized literature platforms (DeepDyve Enterprise) | Small to mid-sized teams with recurring needs | Shared reading, deduplicated purchases, copyright-cleared business use, audit trail | Coverage varies by publisher; you have to check fit against your reading list |
Most companies end up mixing two or three of these, which is reasonable. The mistake is treating the mix as a process when it’s really a series of unrelated individual decisions.
A note on Sci-Hub in corporate environments
Sci-Hub comes up in most conversations about corporate access, usually off the record.
Sci-Hub surfaced real questions about the economics of scholarly publishing, and a generation of academics used it because the legal routes were genuinely too slow or too expensive. That history is worth acknowledging.
The corporate situation differs in two specific ways. The entity using the paper is a company, not an individual, which changes the copyright analysis and the discovery risk; a PDF that traveled through Sci-Hub and then into a regulatory submission will eventually surface for your general counsel. And Sci-Hub stopped adding new papers in late 2021, the Delhi High Court case is still unresolved as of early 2026, and the mirror landscape keeps shrinking. Even setting aside the legal exposure, it’s a weak dependency for any team that needs literature from the last four years.
For working researchers inside companies, the legal alternatives have caught up enough to be real answers rather than bad-faith compromises.
The problems with ResearchGate and academic library affiliations
ResearchGate is a huge social network of scientists where users can connect with fellow researchers and request access to their published works. For many startups, ResearchGate is a wonderful resource to request papers. Another avenue for startups is to request papers from scientific advisors and academic colleagues who can leverage their academic library.
Getting papers from ResearchGate and scientific/academic connections can prove problematic for startups however in several ways. First, it can be time consuming waiting to hear back from these connections in the hopes that they respond with a paper, and time is of the essence. Second and perhaps most importantly, these papers usually have copyright restrictions and may not be used for commercial purposes or outside the academic institution, so organizations need to be careful.
Why direct purchasing breaks at team scale
Buying one paper from the publisher works when one person needs one specific article right now. The model breaks around the fifth or sixth purchase, when a team starts buying in parallel without coordination. Furthermore, the licensing terms of individual article purchases at publisher sites often limit usage of the paper to non-commercial use, and only for the individual person making the purchase; i.e., it’s not permitted to share the paper even within the company.
A medical affairs team of seven at a mid-cap pharma can easily pull forty to sixty papers a month between literature monitoring, congress prep, and field medical inquiries. At a typical $42 per article, that’s $1,700 to $2,500 a month in publisher transactions. The invisible cost runs higher: two analysts buying the same paper a week apart because there’s no shared index, a third analyst skipping a paper she actually needs because the rental felt hard to justify, and a fourth keeping the PDF on her laptop where nobody else can find it when she leaves.
The budget line item undersells what the company is actually spending.
What centralized, copyright-cleared access changes
A shared setup is cheaper, and it also produces a defensible record of what the team read, when, and under what license.
In practice, that looks like one approved search-and-read interface, one invoicing relationship, one place where annotations and saved references live, and one log that compliance can point to when someone asks how the team evidences its claims. The same paper isn’t bought twice, and the analyst who’s been with the company for six months can see what the analyst who left last year had already read on the topic.
DeepDyve Enterprise is built for that pattern. It gives corporate teams copyright-cleared access, team libraries, duplicate-purchase detection, and shared annotation. The AI Research Assistant and reference manager live in the same environment, which matters when the team is trying to cut handoffs between search, reading, and citation.
DeepDyve’s LitStream collection does not currently include Elsevier titles, so if your team’s reading list is heavy on Cell, The Lancet, or Trends-family journals, map coverage against your actual journal list before signing anything. The DeepDyve Personal plan is also not licensed for business use; corporate teams need the Enterprise track.
When to centralize
A shared access setup starts paying for itself when any two of these are true:
- Multiple employees read paywalled papers most weeks
- The same literature gets referenced across R&D, regulatory, safety, and medical writing
- Article purchases are already a recurring line in expense reports
- A regulator or auditor would want an evidence trail for which papers informed which decisions
- People are sharing PDFs informally because there’s no sanctioned way to do it
Once two of those hold, the decision is about process risk rather than cost per article.
A short decision framework
If full-text demand is genuinely occasional, open access plus the occasional publisher purchase is enough. Track the purchases in one place so you can see when the pattern shifts.
If demand is frequent but unpredictable, a document delivery vendor like Reprints Desk or RightFind handles the long tail without committing to a site license. Expect to pay $35-$50 per article including copyright fees.
If literature reading is a routine input across more than one function, set up a shared access process. For most teams under fifty researchers, that’s a centralized platform like DeepDyve Enterprise. For larger organizations with concentrated reading on a few publishers, a negotiated site license probably wins on coverage even if it loses on flexibility.
Choose the smallest structure that makes the team’s literature use defensible.
FAQ
What is the safest way for a company to access scientific papers legally? Use approved channels: open access where it covers the field, direct publisher purchase for occasional urgent needs, document delivery vendors for the long tail, and a centralized platform or site license for recurring team access. The right mix depends on volume and which publishers your reading list actually leans on.
Why are Sci-Hub, ResearchGate and academic library affiliations a poor fit for companies? The copyright permissions are different when the user is a corporate entity or not directly affiliated with the academic library, and a Sci-Hub-sourced paper showing up in a regulatory submission or patent prosecution file creates discovery problems your legal team won’t enjoy. Sci-Hub has also added no new papers since late 2021, so it’s a weak dependency for current literature regardless of the legal question.
Is paying for individual articles a good long-term strategy? For one-off urgent needs, yes. As a steady-state habit for a team of more than three or four people, no. Per-article purchasing hides cost in duplicate buying, scattered archives, and missing audit trails.
What’s the difference between a centralized platform and just buying articles as needed? A platform turns access into a shared process: one license posture, one invoicing relationship, one searchable archive, and deduplication across the team. Ad-hoc purchasing is a series of individual transactions with no memory.
Can companies use DeepDyve’s Personal plan? No. The Personal plan is licensed for individual, non-commercial use. Corporate teams need DeepDyve Enterprise.
Does DeepDyve cover every publisher? No. Elsevier titles are not in the LitStream collection, and coverage varies across other publishers. Map your team’s actual reading list against the collection before committing.
Give it a Try
If your team is still handling journal access one card swipe at a time, talk to a DeepDyve client specialist about Enterprise and walk through whether a shared, copyright-cleared setup fits the way your team actually reads.